Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up

Abstract

The long-term outcome of patients with haematological malignancies treated with reduced-intensity conditioned allogeneic peripheral blood stem cell transplantation is not known. We report the outcome of 79 patients with poor-risk myeloid and lymphoid malignancies transplanted with reduced-intensity conditioning (RIC) regimens. The diagnoses include AML/myelodysplastic syndrome (n=43), non Hodgkin's lymphoma (n=30), Hodgkin's lymphoma (n=3), ALL (n=2) and CML (n=1). For the entire cohort, the disease-free survival (DFS) and OS were 61.2 and 35.7%, respectively. Twenty patients relapsed, 18 within the first three years, and 14 patients succumbed to progressive disease. Overall, 31 patients died from transplant-related complications within the first three years. Day 100 non-relapse mortality correlated with a higher total nucleated cell dose in the graft (odds ratio: 3.9). For those in CR at 3 years, the DFS and OS were 84.2 and 81.1%, respectively. Furthermore, of 43 patients with active disease at the time of transplantation, 16 remained in CR after 3 years. The majority of the long-term survivors were functioning independently. One patient died from a second malignancy. No post-transplant lymphoproliferative disorder was seen. In conclusion, durable disease control was achieved after RIC allogeneic stem cell transplantation for patients with advanced myeloid and lymphoid malignancies.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Estey EH . Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000; 14: 476–479.

    Article  CAS  PubMed  Google Scholar 

  2. Peniket AJ, Ruiz DEM, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplantation for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667–678.

    Article  CAS  PubMed  Google Scholar 

  3. Gajewski JL, Phillips GL, Sobocinski KA, Armitage J, Gale R, Champlin R et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 14: 572–578.

    Article  CAS  PubMed  Google Scholar 

  4. Collins Jr RH, Shpilberg O, Drobyski WR, Porter D, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  PubMed  Google Scholar 

  5. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine-analog-containing regimens: reduced intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.

    Article  CAS  PubMed  Google Scholar 

  6. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier B, Molina A, Maloney D et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high dose cytotoxic therapy with graft-versus-host tumor effects. Blood 2001; 97: 3390–3400.

    Article  CAS  PubMed  Google Scholar 

  7. Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet F, Shizuru J et al. Protective conditioning for acute graft-versus-host disease. N Eng J Med 2005; 353: 1321–1331.

    Article  CAS  Google Scholar 

  8. Corradini P, Tarella A, Olivieri A, Gianni A, Voena C, Zallio F et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99: 75–82.

    Article  CAS  PubMed  Google Scholar 

  9. Hertzberg M, Grigg A, Gottlieb D, Szer J, Roberts A, Hoyt R et al. Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. Bone Marrow Transplant 2006; 37: 923–928.

    Article  CAS  PubMed  Google Scholar 

  10. Khouri I, McLaughlin P, Saliba R, Hosing C, Korbling M, Lee M et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after non-myeloablative conditioning with fludarabine, cyclophosphamide and rituximab. Blood 2008; 111: 5530–5536.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006; 37: 439–449.

    Article  CAS  PubMed  Google Scholar 

  12. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A et al. Early blast clearance by remission induction chemotherapy is a major independent prognostic for both achievement of complete remission and long-term outcome in acute myeloid leukemia: Data from the German AML cooperation group (AMLCG) 1992 trial. Blood 2003; 101: 64–70.

    Article  CAS  PubMed  Google Scholar 

  13. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial—The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333.

    CAS  PubMed  Google Scholar 

  14. Appelbaum FR . Who should be transplanted for AML. Leukemia 2001; 15: 680–682.

    Article  CAS  PubMed  Google Scholar 

  15. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem cell transplantation using reduced intensity conditioned regimen has the capacity to produce durable remissions and long-term disease free survival in patients with high-risk acute myeloid leukaemia and myelodysplasia. J Clin Oncol 2005; 23: 9387–9393.

    Article  CAS  PubMed  Google Scholar 

  16. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ . Sequential regimen of chemotherapy, reduced intensity conditioning for allogeneic stem cell transplantation and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675–5687.

    Article  PubMed  Google Scholar 

  17. Socie G, Stone JV, Wingard J, Weisdorf D, Henslee-Downey P, Bredeson C et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. N Eng J Med 1999; 341: 14–21.

    Article  CAS  Google Scholar 

  18. Bhatia S, Francisco L, Carter A, Sun C, Baker K, Gurney J et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long term survivors: report from Bone Marrow Transplant Survivor Study. Blood 2007; 110: 3784–3792.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Aoudjhane M, Labopin M, Gorin M, Shimoni A, Ruutu T, Kolb H et al. Comparative outcome of reduced intensity And myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukaemia Working Party (ALWP) of European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304–2312.

    Article  CAS  PubMed  Google Scholar 

  20. Scott BL, Sandmaier BM, Storer B, Maris M, Sorror M, Maloney D et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukaemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20: 128–135.

    Article  CAS  PubMed  Google Scholar 

  21. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20: 322–328.

    Article  CAS  PubMed  Google Scholar 

  22. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al. Retrospective comparison of reduced intensity conditioning and conventional high dose conditioning for allogeneic haematopoietic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836–846.

    Article  CAS  PubMed  Google Scholar 

  23. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Non-myeloablative versus reduced intensity conditioning regimens in the treatment of acute myeloid leukaemia and high risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic haematopoietic stem cell transplantation. Blood 2004; 104: 865–872.

    Article  CAS  PubMed  Google Scholar 

  24. Lee SJ, Klein JP, Barrett J, Ringden O, Antin J, Cahn J et al. Severity of chronic graft-versus-host disease: association with treatment related mortality and relapse. Blood 2002; 100: 406–414.

    Article  CAS  PubMed  Google Scholar 

  25. Byrne JL, Stainer C, Cull G, Haynes A, Bessell E, Hale G et al. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft versus host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplant 2000; 25: 411–417.

    Article  CAS  PubMed  Google Scholar 

  26. Sierra J, Storer B, Hansen JA, Martin P, Petersdorf E, Woolfrey A et al. Unrelated donor marrow transplantation for acute myeloid leukaemia: an update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397–404.

    Article  CAS  PubMed  Google Scholar 

  27. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino E, Bartolomeo P et al. Antithymocytic globulin for graft versus host disease prophylaxis in transplants from unrelated donors: 2 randomised studies from Gruppo Italiano Midollo Osseo (GITMO). Blood 2001; 98: 2942–2947.

    Article  CAS  PubMed  Google Scholar 

  28. Morris ES, MacDonald KPA, Hill G . Stem cell mobilisation with G-CSF analogs: a rational approach to separate GVL and GVDH? Blood 2006; 107: 3430–3435.

    Article  CAS  PubMed  Google Scholar 

  29. Rizzo DJ, Curtis RE, Socie G, Sobocinski K, Gilbert E, Landgren O et al. Solid cancers after allogeneic haematopoietic cell transplantation. Blood 2009; 113: 1175–1183.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Landgren O, Gilbert ES, Rizzo D, Socie G, Banks P, Sobocinski K et al. Risk factors for lymphoproliferative disorders after allogeneic haematopoietic cell transplantation. Blood 2009; 113: 4992–5001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S Patil.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patil, S., Spencer, A., Schwarer, A. et al. Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up. Bone Marrow Transplant 45, 1154–1160 (2010). https://doi.org/10.1038/bmt.2009.322

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.322

Keywords

This article is cited by

Search

Quick links